News Releases

Pharming Group presents its preliminary (unaudited) financial report for the first nine months ended September 30, 2021. The Company held a presentation for analysts at 13:30CET/07:30ET on 28 October 2021. To watch the recording of the call please follow the link below:

Pharming Group N.V. (“Pharming” or “the Company”) (Euronext Amsterdam: PHARM/NASDAQ: PHAR) announces the topline results from two randomized, open label, controlled, pilot clinical trials of patients hospitalized with COVID-19 treated with RUCONEST® (recombinant human C1 inhibitor) for the

Recovery continued into Q2 2021 as patient enrollment and product demand increases. Pharming Group presents its preliminary (unaudited) financial report for the first six months of 2021 ended June 30, 2021. The company held an analyst call at 13:00CET, to rewatch the analyst call please go

Pharming Group announces it has entered into an exclusive licence agreement with NewBridge Pharmaceuticals (“NewBridge”) for the distribution of RUCONEST® (conestat alfa) in the Middle East and North Africa (“MENA”).  

Orchard Therapeutics, a global gene therapy leader, and Pharming Group, a global, commercial stage biopharmaceutical company, today announced a strategic collaboration to research, develop, manufacture and commercialize OTL-105, a newly disclosed investigational ex vivo autologous hematopoietic

Pharming announces the successful completion of patient enrolment in the  pivotal Phase II/III triple-blind, randomized, placebo-controlled study of leniolisib for the treatment of activated phosphoinositide 3-kinase delta (PI3Kδ) syndrome (APDS).

Pharming Group announces the appointment of Anurag Relan as Chief Medical Officer (CMO), effective immediately, and Robert Friesen as Chief Scientific Officer, effective from 1 August 2021. Anurag and Robert will be the successors of Bruno Giannetti, who was Chief Operating Officer (2006 - 2019)

Pharming Group N.V. announces that an agreement has been reached with the Spanish Ministry of Health to grant reimbursement for RUCONEST® (conestat alfa) in Spain.

Pharming Group N.V. announces that its Chief Executive Officer, Sijmen de Vries, will present at the Jefferies Virtual Healthcare Conference 2021 at 14:30-14:55 CET/08:30-08:55 EDT on 4 June 2021.

Pharming Group N.V. announces that at its Annual General Meeting of shareholders (AGM), held today, all proposals were approved.